SCHEMBL732579

SCHEMBL732579

O=C(O)c1cc(C(=O)O)cc(N2CCCC2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.67
KDM4E B2RXH2 5/20 0.67
HPGD P15428 4/20 0.67
HSD17B10 Q99714 3/20 0.67
GAA P10253 3/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
IP6K1 Q92551 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.48
NPC1 O15118 2/20 0.48
TP53 P04637 2/20 0.48
MAPT P10636 2/20 0.48
TSHR P16473 2/20 0.48
RAB9A P51151 2/20 0.48
LMNA P02545 1/20 0.48
ALOX15 P16050 1/20 0.48
STAT1 P42224 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
POLB P06746 2/20 0.47
KMO O15229 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14153131 0.88 KDM4E (0.54) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL594366 0.87 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL730950 0.86 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL592613 0.85 KDM4E (0.56) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL594127 0.85 KDM4E (0.56) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2724983 0.85 ALDH1A1 (0.56) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL21817818 0.84 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL4727601 0.82 HPGD (0.53) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL27893364 0.82 KMO (0.70) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL15122991 0.81 KDM4E (0.51) ALDH1A1KDM4EHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 ALDH1A1 113/4885KDM4E 3445/4885HPGD 2417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.